Fe3 Medical Gets $11M For Anemia Patch

San Antonio-based Fe3 Medical, a company developing a transdermal patch to help patients with iron-deficiency anemia, has raised $11M in a funding round, the company said this week. The SEries B funding came from Jianmin Pharmaceuticals, HG Capital and PingAn Ventures, along with InCube Ventures. Fe3 Medical's transdermal patch delivers iron to anemic patients. The company said the funding goes towards clinical trials and regulatory submissions, which are required for both CE Mark and FDA approval. As part of the funding, the company says it has named Mark Sieczkarek as CEO of the company; Sieczkarek led Solta Medical (acquired by Valeant Pharmacuticals), Conceptus (acquired by Bayer Pharmaceuticals), and has served at Bausch & Lomb and Bristol-Myers Squibb, and currently serves as Chairman of NovaBay. More information »